We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood-Brain Barrier Imaging Adds Risk Insight to Standard Stroke MRI

By HospiMedica International staff writers
Posted on 13 May 2026

Acute ischemic stroke requires fast, precise decisions on reperfusion and bleeding risk, yet routine imaging gives limited insight into vascular integrity. More...

Clinicians need ways to predict outcomes and tailor therapy in time-critical settings. Blood–brain barrier failure, a marker of tissue injury and inflammation, has been difficult to visualize in everyday practice. To help address this challenge, researchers have developed “blood-brain core” or “leaky core” information derived from existing magnetic resonance imaging (MRI) data to individualize stroke care.

Blood-brain core imaging is an algorithmic method developed through a multi-institutional collaboration involving the Johns Hopkins University School of Medicine. The approach quantifies blood-brain barrier disruption on standard post-stroke MRI by analyzing a sequence already acquired in many acute scans. It calculates the extent of vascular leakage within affected brain regions, producing an index that captures permeability changes linked to injury and inflammation and may indicate heightened risk for post-ischemic hemorrhage.

In a review of 291 post-stroke brain scans by researchers from France, the U.S., and Spain, the team localized areas of blood–brain barrier disruption and linked them to outcomes. For every 1% increase in disruption measured by the index, the odds of a poor outcome at three months after ischemic stroke rose by 16%. The study, titled “Core Blood-Brain Barrier Disruption in Patients With Large Vessel Occlusion,” was published in Stroke.

Applied clinically, the imaging may refine therapy selection and sequencing. Patients with evidence of leakage may still be eligible for mechanical thrombectomy, while clinicians withhold blood thinners or forego clot‑dissolving medication after the procedure to limit bleeding risk. Conversely, patients who appear unlikely to benefit on conventional imaging but show intact vessels on leaky core imaging could receive treatment, potentially expanding access to interventions previously considered unsuitable.

Beyond acute decision-making, the method could streamline targeted clinical trials by identifying therapies that preserve the blood–brain barrier using fewer resources. It may also help monitor patients after stroke who face elevated risks of a second stroke or dementia, enabling earlier opportunities to intervene. Because the algorithm leverages MRI sequences already collected in standard scans, it can be computed from existing data without additional image acquisition, adding actionable information to personalize care.

"We are constantly advancing our stroke prevention strategies, our acute stroke treatments, our post-stroke management and our stroke rehabilitation options," says Richard Leigh, M.D., the first study author, a neurologist and the director of the Johns Hopkins Neuro Vascular Brain Imaging Laboratory. "It is likely that imaging the blood-brain barrier, which is itself a marker of brain health, can help us improve all of these interventions."

Related Links
Johns Hopkins University School of Medicine


Gold Member
12-Channel ECG
CM1200B
Gold Member
Blood Gas Analyzer
i-Check200
Patient Preoperative Skin Preparation
BD ChloraPrep
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.